INTRODUCTION
Adeno-associated virus (AAV)-based vectors are emerging as favorable candidates for use in gene therapy protocols. They are derived from a nonpathogenic virus, infect a broad range of tissue (24) , and have elicited few cytotoxic effects or adverse immune reactions in animal models (2, 6, 7, 10, 15, 27, 28) . Because it can transduce nondividing cells (26) , AAV may be well-adapted for delivering genes to the central nervous system (CNS).
AAV vectors containing therapeutic genes have been
shown to transduce mammalian brain and to have func tional effects in animal models of disease. For example, infusion of an AAV vector containing the human tyro sine hydroxylase (TH) gene into adult rat brain resulted in transduction of both neurons and glia (13, 14) . Deliv ery of the same vector to monkey striatum resulted in robust expression of TH for up to 3 months (2) . Further more, AAV-TH was tested in a rodent model of Parkin son's disease where it demonstrated the ability to cause significant improvement in rotational behaviors of 6-hydroxydopamine-lesioned rats (13) . AAV has also been used to transfer the thymidine kinase (TK) gene to ex perimental gliomas in mice, and the ability of AAV-TK to render these brain tumors sensitive to the cytocidal effects of ganciclovir has been demonstrated (22, 25) .
While reports such as these demonstrate AAV's poten tial for targeting the CNS, the relationship between dose of injected vector and its resulting distribution in brain tissue has not been previously reported.
Direct intraparenchymal injection of proteins into the brain, either by convection-enhanced delivery (CED) or bolus injection, can achieve high drug concentrations at specific sites (19) . CED (infusions that are performed while maintaining a pressure gradient over time) has been shown to distribute molecules to large areas of brain tissue (up to several square centimeters) in both rats and rhesus monkeys (19) . Alternatively, delivery by bolus injection relies on diffusion alone and results in high concentrations of drug in tissue surrounding the needle tract with otherwise limited distribution. Bolus injection of viral vectors into the CNS could potentially have toxic effects due to the overexpression of gene product in a limited area and, furthermore, may necessi tate multiple injections in order to encompass the tar geted region. Application of CED to the administration of viral vectors might improve the spread of vector parti cles in brain and result in more uniform transgene ex pression over larger regions of the brain (1,2).
To test different doses of an AAV vector for efficient transduction in brain, 2.5 x 10 8 , 2.5 x 10 9 , and 2.5 x 10 H)
particles of AAV-TK were stereotactically infused into the striatum of adult rats using CED. Serial coronal sec tions were immunoperoxidase-labeled and transgene ex pression was quantitated with the aid of image analysis software. Because attempts to administer therapeutics to brain often meet notable obstacles, two different CED methods were compared for their ability to safely and efficiently deliver AAV vector. We used Alzet minipumps, which are capable of infusing fluid into the brain parenchyma via CED over a longer period of time, and a mechanical pump for acute CED of AAV. PCR analy sis was also performed on a wide array of tissue and organs to determine vector distribution following intra cranial delivery. Comparisons were not made directly to bolus-injected tissue.
MATERIALS AND METHODS

Construction of pTKl
The pTKl plasmid was constructed by placing the herpes simplex virus thymidine kinase gene (HSV1 TK) under the transcriptional control of the cytomegalovirus (CMV) immediate early promoter (Fig. 1 ). An intron sequence made up of a CMV splice donor and a y-globin splice acceptor was located directly upstream of the TK gene and the human growth hormone polyadenylation sequence (hGH poly A) was placed downstream. Se quence from bacterial P-galactosidase (LacZ spacer) was also placed downstream of the expression casette to achieve optimal viral packaging size. The entire se quence was flanked by AAV inverted terminal repeats (ITRs) that are required for vector replication and pack aging. The construct was propagated in a Kanscriptbased plasmid. pTKl was used in the production of AAV-TK.
AA V Vector Production
Recombinant AAV virions (AAV-TK) were pro duced in human embryonic kidney 293 cells using an adenovirus-free system as described by Matsushita et al. (21) . Vector titer was 6.4 x 10 12 particles/ml as deter mined by quantitative dot-blot hybridization. 
In Vivo Gene Delivery
Female Sprague-Dawley rats (250-300 g) from Charles River Laboratories (Wilmington, MA) were an esthetized with an IP injection of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight) and prepped for surgery. During surgery, sedation was main tained with isoflorane (Aerrane, Omeda PPD Inc., Lib erty, NJ) and 0 2 flow rates were kept at 0.3-0.5 L/m. The head of each rat was fixed in a stereotactic appara tus (Small Animal Stereotactic Frame; ASI Instruments, Warren, MI) with ear bars, and a midline incision was made through the skin to expose the cranium. A bunhole was made in the skull 1 mm anterior to bregma and 2.6 mm lateral to the midline using a small dental drill. Convection-enhanced delivery (CED) of vector to the left hemisphere at a depth of 5 mm was performed using an infusion pump or subcutaneous osmotic pumps.
For dosage studies, there were three groups of ani mals with six animals per group. AAV-TK was continu ally administered to each rat at a rate of 8 pl/h for 2.5 h using a Harvard infusion pump (Harvard Apparatus, Inc., Holliston, MA). The loading chamber (Teflon tub ing, 1/16" ODxO.03" ID) and attached infusion cham ber (1/16" OD x 0.02" ID) were filled with 2.5 x 10*, 2.5 x 10', or 2.5 x 10"' particles of AAV-TK in a total vol ume of 20 pi artificial cerebrospinal fluid (csf) (148 mM NaCl, 3 mM KC1, 1.4 mM CaCL 2H 2 0, 0.8 mM MgCl, 6H 2 0, 1.3 mM Na 2 HPQ 4 H 2 0, 0.2 mM NaH 2 P0 4 H 2 0). For routine histological analysis, every 12th section was stained with H&E. Selected sections representing differ ent brain regions were stained with cresyl violet in order to determine general cell density.
PCR Analysis
To determine extracranial tissue distribution of AAV, three additional rats were treated with 2.5 x 10 l(l parti cles AAV-TK using CED for the purpose of determining tissue distribution of vector. Two of the rats received vector by infusion pump and the other by osmotic pump, as described above. Animals were euthanized 3 weeks later using C0 2 inhalation and samples from 15 organs and tissues were harvested from each rat including right brain, left brain, spinal cord, right eye, left eye, heart, lung, liver, kidney, spleen, ovary, thymus, lymph node, bone marrow, and leg muscle. Sterile techniques were used and tissue was collected using disposable suture removal kits that were changed between each sample.
Tissues were immediately frozen in liquid N 2 and kept at -70°C until they were processed for genomic DNA.
PCR was performed using Perkin Elmer's GeneAmp n is the number of stained sections.
RESULTS
Vector Titer Influences Transgene Expression
To determine the amount of vector that is required to transduce brain tissue, comparisons of immunostained sections were performed between rats receiving 2.5 x for the low-dose group ( Fig.   2A ). Volumes were calculated from the mean areas and lengths of tissue staining, which both showed significant differences between the groups (Fig. 2B, C) . Further more, the total number of TK-positive cells in sections from the high-dose group, estimated to average 169,000, was lOx higher than that of the middle dose group (Fig.   2D ). Expression within a volume of transduced tissue was not uniform, but exhibited a gradient of staining.
Areas directly surrounding the injection sites were sometimes heavily labeled while fewer positive cells could be detected as distance from the needle tract in creased (Fig. 3) . In the majority of animals, however, extensive transgene expression could be detected in the striatum and areas far removed from the site of delivery (Fig. 3A, C) .
Infusion Pump Versus Osmotic Pump Delivery
To investigate whether or not sample volume affects transduction efficiency when the rate of infusion is kept constant, rats were given 2. 
C). Efficient transduction is depicted directly surrounding site of infusion (B) as well as in areas further removed (A and C). Cortical lesion that is seen in (A) is a result of craniotomy. Original magnification lOx.
Comparisons of immunostained brain sections demon strated similarities and differences in the abilities of the two pumps to deliver vector using CED. There was no significant difference in TK expression between the two groups as measured by mean volume of staining, area, AP distance, and total estimated number of positive cells (Fig. 4A-D) . However, there was some tissue loss sur rounding the needle tracts of all of the samples within the osmotic pump delivery group (Fig. 6) . While both delivery methods resulted in notable transgene expres sion, there was a difference in the type of cells that be came labeled. Tissue infused with vector appeared to express TK almost predominantly in cells with morpho logical features of neurons (Fig. 5A, B) , whereas tissue receiving vector via osmotic pump appeared to express TK in cells with morphological features of both neurons and reactive glia close to the injection site (Fig. 6B) .
Toxicity
To assess toxicity, histopathology was performed on H&E sections from each of the dosage and delivery groups and the results are summarized in Table 1 . In the infusion groups, tissue damage was absent or minimal. There was no cellular infiltration, no necrosis in the nee dle tract, and minimal cortical necrosis in a few of the animals. Fresh bleeding was found in one of the highdose rats and hemosiderosis, indicating moderate bleed ing prior to tissue harvest, was found in four of the highdose animals. Alternatively, serious damage was noted in all of the animals in the osmotic pump delivery group including large necrotic areas surrounding the needle tract, cellular infiltrate, and hemosiderosis. The presence of fresh blood in all of the animals in this group 2 weeks after surgery indicates ongoing hemorrhage.
Tissue Distribution
To determine if recombinant AAV could be detected at locations distant from the site of intracranial delivery, PCR analysis was performed on 15 different organs and tissue from each of three rats that had received a high dose of vector. Regardless of the delivery method (infu sion or osmotic pumps), a 458-bp PCR product from the TK gene could be detected in both hemispheres of the brain, spinal cord, and spleen using Southern blot analy- sis (Fig. 7) . In one of the rats, vector was also detected in the kidney.
DISCUSSION
Our results demonstrate that gene delivery to the A comparison of two different pump systems sug gests that distribution of vector (as determined by immu nostaining of the transgene product) is primarily depen dent upon dose (particle number) and not sample volume or duration of delivery. The distribution of 2.5
x 10 10 particles (high dose) was the same whether it was delivered by osmotic pump or slow infusion pump even though there was a 10-fold difference in both sample volumes and times of delivery between the two groups.
As mentioned above, strikingly different levels of ex pression were observed between the three dosage groups that all received vector by slow infusion. In that case, sample volume, rate, and delivery time were kept con stant and particle number was the only variable. Addi tional studies need to be done that individually assess volume, rate, and delivery time to confirm this observa able to show that number of viral adeno-viral particles, but not volume of infusate, was the limiting factor in transduction volume in the rodent brain.
Because dose has the most profound effect on distri bution and because the ability to concentrate viral stocks is limited by current production technology, the ability to deliver relatively large volumes of stock virus is de sirable. In our experience, limited volumes of vector can be delivered to the brain using manual injection tech niques before leakage occurs at the injection site, while slow infusion can be used to successfully administer larger volumes and, thus, a higher dose of vector. While SC-implanted osmotic pumps have an even greater ca pacity for delivery, our study suggests that their use for intracranial viral gene therapy may result in toxicity. However, these pumps have been used in many animal models to safely deliver other therapeutics intracerebrally (11, 20, 23) . Further studies that test smaller os motic pump models, lower flow rates, and more expedi tious removal of the cannula may achieve vector delivery without damage and improve the toxicity pro file.
We and others have reported that AAV vectors are capable of transducing neurons (2, 3, 9, 14, 16) , and the present study confirms this finding. The prominent ex pression in cells bearing morphological features of neu- Figure 7 . PCR analysis to determine tissue distribution of vector following intracranial delivery. Particles (2.5 x 10 10 ) of AAV-TK were administered intracranially to one rat using osmotic pump (A) and to two rats using infusion pumps (B and C). Three weeks later, samples from 15 organs and tissues were harvested from each rat including right cerebral hemisphere (RB), left cerebral hemisphere (LB), heart (Ht), lung (Lu), liver (Li), kidney (Ki), spleen (Sp), right eye (RE), left eye (LE), ovary (Ov), spinal cord (SC), bone marrow (BM), lymph node (LN), leg muscle (Mu), and thymus (Th). Southern blot analysis was used to detect 158-bp PCR products in samples where vector was present. Three positive plasmid controls for the PCR reaction were also included (A only), and consisted of 100,000, 1000, or 10 copies of TK. 
